Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) by 60 percent. This is a 5.88 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $15.009 million which beat the analyst consensus estimate of $14.933 million by 0.51 percent. This is a 1.04 percent increase over sales of $14.855 million the same period last year.